Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company’s lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.
NASDAQ ADRO (Common Stock) 0.251.69%)September 23, 20164:00 p.m. ET
September 22, 2016 Aduro Biotech to Present at LEERINK Partners Roundtable Series
Events & Presentations
|Data Provided by Thomson Reuters|